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DETECTION OF PARVOVIRUS B19 INFECTION IN FORMALIN-FIXED AND PARAFFIN-EMBEDDED
PLACENTA AND FETAL TISSUES
Paulo Roberto Veiga QUEMELO(1), Danielle Malta LIMA(2), Benedito Antônio Lopes da FONSECA(2) & Luiz Cesar PERES(1)
SUMMARY
Parvovirus B19 infection was first discovered in 1975 and it is implicated in fetal death from hydrops fetalis the world over.
Diagnosis is usually made through histological identification of the intranuclear inclusion in placenta and fetal organs. However,
these cells may be scarce or uncharacteristic, making definitive diagnosis difficult. We analyzed histologically placentas and fetal
organs from 34 cases of non-immune hydrops fetalis, stained with Hematoxylin and Eosin (HE) and submitted to
immunohistochemistry and polymerase chain reaction (PCR). Of 34 tissue samples, two (5.9%) presented typical intranuclear
inclusion in circulating normoblasts seen in Hematoxylin and Eosin stained sections, confirmed by immunohistochemistry and
PCR. However, PCR of fetal organs was negative in one case in which the placenta PCR was positive. We concluded that parvovirus
B19 infection frequency is similar to the literature and that immunohistochemistry was the best detection method. It is highly
specific and sensitive, preserves the morphology and reveals a larger number of positive cells than does HE with the advantage of
showing cytoplasmic and nuclear positivity, making it more reliable. Although PCR is more specific and sensitive in fresh or
ideally fixed material it is not so in formalin-fixed paraffin-embedded tissues, frequently the only one available in such cases.
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INTRODUCTION
Parvovirus B19, the virus responsible for the erythema infectiosum,
was discovered in the U.K. in 1975 by COSSART et al., who identified
the virus in the serum of a healthy blood donor5. It is the only pathogenic
human virus belonging to the Parvoviridae family and having a
worldwide distribution2.
Transmission of the virus is through airway secretions and blood2,17.
In temperate countries, infection is more common from the end of
winter to the beginning of summer and there are spikes in frequency
every three to four years1,28, a finding also reported in a study from Rio
de Janeiro, Brazil24.
The percentage of individuals that have come into contact with the
parvovirus B19 virus increases in parallel with the age of the individual,
reaching 75% by the age of 504,28. In Rio de Janeiro, Brazil, IgG for
parvovirus B19 was detected in 35% of children under five years of
age, in 80% of teenagers from 11 to 15 and in over 90% of adults older
than 5023.
Although post-natal parvovirus B19 infection is usually mild, either
completely asymptomatic or manifested by erythema infectiosum, fever,
arthropathy, malaise or myalgia3,19,13 the disease may be life-threatening
during fetal life. Vertical transmission, which occurs in over 30% of
cases3,28, may result in fetal hydrops or abortion9,26,33. The virus replicates
in erythroid precursors2,10,22, resulting in anemia. More recently, it has
been shown to infect cardiomyocytes25, which, together with the anemia,
can induce heart failure and fetal hydrops.
Diagnosis of parvovirus B19 infection in formalin-fixed, paraffin
embedded tissue can be made through the identification of the
characteristic brick-red intranuclear inclusions in normoblasts within
the fetal circulation in histological sections stained with Hematoxylin
and Eosin (HE)29, by immunohistochemistry20,32 or by PCR15,21,28. These
methods differ in respect to ease of use, cost, sensitivity and specificity,
all of which must be taken into account when selecting a technique for
routine diagnostic use.
The present study aimed to determine the frequency of parvovirus
B19 infection in cases of non-immune fetal hydrops or diffuse villous
edema in the placenta in tissues fixed in formalin and embedded in
paraffin examined at the Ribeirão Preto School of Medicine University
Hospital using the three aforementioned methods.
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MATERIAL AND METHODS
The Ethical Research Committee of the Ribeirão Preto School of
Medicine University Hospital approved this study (No. 3830/2003).
A total of 34 formalin-fixed, paraffin-embedded tissue samples
were used, of which 26 were placentas from well-formed fetuses with
non-immune hydrops, and eight were tissue fragments obtained through
curettage. The latter presented diffuse villous edema and few or no
fetal fragments. The patients from whom the samples were collected
had been previously examined at the University Hospital from January
1998 to December 2002.
Two 4 µm-thick histological sections were taken from each case
for HE and immunohistochemical staining, respectively, the latter over
silane-coated slides.
Antigenic retrieval using steam heat in pH 6.0 citrate buffer was
employed for the immunohistochemical reaction with R92F6 parvovirus
B19 primary antibody (NCL-Parvo, Novocastra, Newcastle upon Tyne,
UK), diluted 1:1500 in BSA and incubated overnight. Subsequently,
the sections were incubated with the secondary antibody (biotinylated,
affinity-purified anti-immunoglobulin; Novocastra, Newcastle upon
Tyne, UK) diluted 1:200 in BSA for 60 minutes. Immunolabelling was
performed by a standard Avidin-Biotin (ABC) technique (Novostain
Super ABC Kit, universal, Novocastra Laboratories, U.K.). The labeling
was developed with 3,3’-diaminobenzidine (DAB; D5638, Sigma, St.
Louis, MO, USA) and the slides were counterstained with Harris
hematoxylin and mounted with Entellan (Merck, USA).
Histological sections (each 5 µm-thick) were cut, using a new, clean
disposable knife for each section, and collected into new clean 1.5-mL
microtubes for PCR. Paraffin was removed by three xylene and two
absolute ethanol washes, followed by DNA extraction with Wizard®
Genomic DNA Purification Kit (Promega Corporation, Madison, WI,
USA). DNA was quantified with a BECKMAN DU-600 spectrophoto-
meter.
As a control for DNA integrity in the PCR amplification reactions,
the endogenous mammalian β-globin gene was also amplified with a
pair of β-globin-specific oligonucleotide primers8.
The DNA amplification was performed as follows: 5 µL of DNA,
23 µL of PCR SUPERMIX (55 mM Kcl, 1.65 mM MgCl2, 220 µM
dGTP, 220 µM dATP, 220 µM dCTP, 220 µM dTTP, 22 U recombinant
TAQ DNA Poly/Ml, Stabilizers), 1 µL of sense primer B19-1, CAA
AAG CAT GTG GAG TGA GG (nucleotides 3187 through 3206) and
1 µL of antisense primer B19-2, CCT TAT AAT GGT GCT CTG GG
(nucleotides 3290 through 3271) were added and put into an Applied
Biosystems Thermocycler, with the following cycle definitions: 94 °C/
5 minutes; 94 °C/1 minute, 50 °C/1.5 minutes, 72 °C/1 minute (35
repetitions after second step), and, finally, 72 °C for five minutes,
obtaining a 104-bp fragment.
Phosphate-buffered saline was used as a negative control and a
sample obtained from a child with a known acute PB19 infection was
used as a positive control.
Following amplification, the material was submitted to agarose
gel electrophoresis (Gibco) in TBE at 80V for one hour, stained with
ethidium bromide, and then photographed.
RESULTS
Of the 34 cases analyzed, recognizable fetuses were observed in
22. Of those 22, 12 were female and 10 were male. The fetuses were
hydropic but presented no other external or internal abnormalities. In
four cases, there were only fragments of placenta and fetuses, and
there was therefore no possibility of macroscopic sex assignment. The
remaining eight cases were represented only by fragments of placenta.
Gestational age ranged from nine to 40 weeks and fetal weight from
34 to 1527 g.
Light microscopy of the placentas of all cases revealed diffuse
villous edema with numerous normoblasts in fetal circulation. Of the
34 cases studied, two (5.9%) presented some normoblasts with the
characteristic parvovirus B19 brick-red intranuclear inclusion seen in
the HE-stained sections (Fig. 1A). In the same two cases, the
Fig. 1 A - Photomicrography of the hematoxylin and eosin (HE)-stained placenta in one of
the positive cases of parvovirus B19 infection. Note the brick-red intranuclear inclusions
(arrows) in the cells of capillaries in the chorionic villi, better seen in the inset (original
magnification, 40x). B - Immunohistochemical staining of parvovirus B19 infected cells
with R92F6 primary antibody. Note cytoplasmic and nuclear labeling seen in a larger number
of cells than that observed in the HE-stained sections (ABC technique, DAB substrate,
Hematoxylin counterstain. Original magnification, 40x)
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immunohistochemical reaction using R92F6 parvovirus B19 primary
antibody was positive in the cytoplasm and nucleus (Fig. 1B), as was
the PCR (Fig. 2). When these methods were applied to histological
sections of fetal organs (heart, lung, kidney and liver) the same two
cases tested positive for parvovirus B19 in the immunohistochemical
and histological analyses, although PCR only showed positivity in one.
No other cell type seen inside fetal vessels, apart from hemopoietic
cells, showed positivity for parvovirus B19. All tissues contained
amplifiable β-globin DNA (data not shown).
Results of clinical and laboratory testing of the two positive cases
are summarized in Table 1, and the various methods are compared in
Table 2.
DISCUSSION
Infection with parvovirus B19 is common in the general population.
The serological prevalence ranges from 75%4,28 to over 90%23 in adults
aged 50 or older, and the infection usually presents as a mild self-
limited disease11. Due to the risk of fetal contamination, serious
consequences may ensue during the childbearing years in women 14,19,28.
In 1995, GRATACÓS et al.11 found a 35.03% prevalence of anti-
parvovirus B19 IgG and 3.7% IgM antibodies in pregnant women at
less than 28 weeks of gestation examined at the Hospital de Clínicas
de Barcelona. In Rio de Janeiro, Brazil, CUBEL et al. tested 28 cases
of non-immune fetal hydrops for parvovirus B19 infections with
different techniques and found six positive cases, one of which had
also a previous diagnosis of syphilis6.
In the present study, two out of 34 cases were positive, resulting in
a prevalence of 5.9% which is within the range of 4% to 16% reported
in the literature7,28. Also in accordance with the literature, the two
positive cases were also second trimester cases6,24,29. The peak in
incidence of parvovirus B19 infection and consequent hydrops in the
second trimester is explained by the substantial increase in blood cell
production and the decrease in fetal tolerance for anemia due to a
small hematological reserve27,29,30. Therefore, the second trimester
represents the best opportunity for clinical diagnosis11,29,32. With the
advent of molecular diagnosis, peak incidence of parvovirus B19
infection has shifted to the end of the third trimester, probably due to
the higher sensitivity of this technique28.
The deleterious action of parvovirus B19 is seen when pregnant
women are infected and the fetus becomes involved. The parvovirus
B19 replicates in red blood cell precursors2,14,22 leading to decreased
production of these cells and, consequently, anemia and myocardial
failure. Infected cells present a characteristic brick-red intranuclear
inclusion seen in HE-stained histological sections, as was observed in
our cases (Fig. 1A).
In the present study, as in most previous studies of such cases, the
only significant findings were fetal hydrops, grade II maceration and
hydropic villi9, although there have been reports implicating parvovirus
B19 in other conditions. WEILAND et al.31 reported a case of parvovirus
B19, diagnosed by dot-blot hybridization, that presented
microphthalmia and lack of an iris and anterior chamber. In contrast,
TOLFVENSTAM et al.28 described cases that were either undetectable
with laboratory test or presented no fetal hydrops or malformation.
Fig. 2 - PCR of the placenta of the two parvovirus B19 infected cases. (M, ladder; C, positive
control; N, negative control; 1, case one; 2, case 2).
Table 1
Clinical and laboratory test data from the two parvovirus B19-positive cases
Case # Malformation GA Sex Weight Necropsy finding Histopathological finding
1 No 19 M 720 g Hydrops fetalis, grade II maceration Circulating normoblasts in placenta
and fetal organs, some with nuclear
inclusion. Diffuse villous edema.
2 No 27 F 1521 g Hydrops fetalis, grade II maceration Circulating normoblasts in placenta
and fetal organs, some with nuclear
inclusion. Diffuse villous edema.
GA, gestational age; M, Male; F, Female; g, gram.
Table 2
Result of the investigation of parvovirus B19 with the various tissues and
techniques used
Case #
1 2
Tissue HE IH PCR HE IH PCR
Placenta + + + + + +
Heart + + + + + -
Liver + + + + + -
Lungs + + + + + -
Kidneys + + + + + -
HE, Hematoxylin and Eosin; IH, Immunohistochemistry; PCR, polymerase chain
reaction.
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Furthermore, WRIGHT et al.32 reported cases that presented cardiac
dilatation, excess lipid accumulation in the adrenal cortex, excessive
iron deposition in the liver and increased placental volume and weight.
Although the replication of parvovirus B19 usually occurs in red
blood cell precursors, recent studies have shown that this virus can
also infect myocardial cells and thus contribute to the heart failure25.
In our cases, employing immunohistochemical and histological analysis
of the placenta and fetal organs, we found that red blood cell precursors
were the only cells infected with parvovirus B19.
Most parvovirus B19-infected cells can be identified through careful
histological examination by an experienced pathologist. However,
immunohistochemical staining highlights a larger number of positive
cells than does HE staining. In addition, since positivity has been found
in the cytoplasm20,32 as well as in the nucleus, the efficiency of
immunohistochemistry may increase in studies with larger samples.
The PCR method is known to be highly specific and sensitive,
although some difficulties arise in formalin-fixed and paraffin-
embedded tissue16, as evidenced by the negative result in the fetal organs
(although positive in the placenta) in one of our cases.
Due to crosslinking with proteins, which increases with the duration
of fixation, formalin fixation may damage the DNA16. Contamination
is a serious problem, and precautions, such as the use of surgical masks
and gloves, should therefore be taken18. Finally, the identification of
which cells are involved in the process is lost with this method.
According to GREER et al.12, there are four requirements for
successful PCR in paraffin-embedded tissue: proper fixative, proper
duration of fixation, proper age of the paraffin block, and proper length
of the DNA fragment to be amplified. We have discovered that section
thickness is also important, probably due to the amount of paraffin
and proteins that are not completely eliminated and thereby impair
both the extraction and amplification process.
Despite the small number of positive cases in this study, histological
examination of HE-stained sections allowed the identification of the
same affected cases, but with fewer cells and only the ones with
intranuclear inclusion. Although the low cost, its use in routine diagnosis
as a single method of detection is time consuming, more prone to
underdiagnosis and demands well-trained persons. Although PCR is
more specific and sensitive in material that is fresh or ideally fixed28,
it is not so in formalin-fixed and paraffin-embedded tissues and has
the additional disadvantage of destroying the histological structure.
Immunohistochemistry is highly specific and sensitive, preserves the
morphological characteristics and reveals a larger number of positive
cells than that seen with HE staining, and has the advantage of revealing
cytoplasmic and nuclear positivity, making it a more reliable tool for
investigation and diagnosis of parvovirus B19 infection.
RESUMO
Detecção da infecção pelo parvovírus B19 em placenta e tecidos
fetais fixados em formalina e embebidos em parafina
O parvovírus B19 foi detectado em 1975 e desde sua descoberta
tem se mostrado um agente infeccioso importante em seres humanos,
cujo diagnóstico pode ser feito pelo exame histológico através do
encontro de inclusão nuclear em tecidos fetais ou placentários. No
entanto, estas células podem ser escassas ou não apresentarem
características típicas, dificultando o diagnóstico. Analisamos pla-
centas e órgãos fetais de 34 casos de hidropisia fetal não-imune
corados com Hematoxilina e Eosina (HE) e submetidos à reação em
cadeia da polimerase (PCR) e imuno-histoquímica (IH). Em dois casos
(5,9%) houve positividade na placenta pelo HE, IH e PCR. No entanto,
PCR dos órgãos fetais foi negativa em um destes casos enquanto que
a identificação pôde ser feita por IH e histologia. Concluímos que a
freqüência do parvovírus B19 é similar à literatura e a reação IH foi
o melhor método de detecção, com identificação mais específica e
segura, permitindo identificação citoplasmática, o que não é possível
pelo exame histopatológico. A PCR pode apresentar falsa negati-
vidade, provavelmente pela fixação, não identifica as células e é mais
dispendiosa. Embora mais específica e sensível em material a fresco
ou idealmente fixado isto não ocorre com tecidos fixados em forma-
lina e embebidos em parafina, freqüentemente os únicos disponíveis.
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